Participated · Seed · Sep 2024

Founded in 2022 and headquartered in Tokyo, NEIGHBOR builds original games and branded metaverse activations on Fortnite Creative and Unreal Editor for Fortnite. The studio first gained notice with a haunted-house world promoting Netflix’s “JUNJI ITO MANIAC,” which drew more than 1.2 million visitors and earned praise from Epic Games. NEIGHBOR has since released an original Fortnite title that has attracted over 2.5 million players and regularly sees 3,000+ concurrent users, demonstrating its ability to surface content through Fortnite’s recommendation algorithms. The company’s core strategy is to export Japanese intellectual property—anime, manga, food, music and more—to Fortnite’s predominantly North American Gen-Z audience. Its global development team collaborates with creators worldwide to secure Epic’s Picks placements and sustain community engagement. Industry recognition includes a 2024 NYX Game Awards Silver for Character Design and Gold for Best Metaverse Game. Recent seed capital positions the company to scale additional Japanese IP integrations and expand its player base.

Led · Equity · Jul 2022

ALLM develops ICT mobile solutions to improve clinical collaboration and care coordination, with a flagship solution called Join that supports emergency, acute, and post-acute care. Its cloud-based products are HIPAA-compliant and FDA-approved, and they collect clinical data to support research and quality-improvement initiatives. The company says its solutions reduce clinician burden, create new revenue streams, lower systemic costs, and expand access by building virtual care networks that go beyond single health systems or EMRs. ALLM will use the financing to accelerate digital transformation (DX) in medical and nursing care, develop telemedicine-specific solutions, and connect existing offerings with IoT devices. The company plans further global expansion, targeting the U.S., Japan, and other overseas markets. The press release was issued from Cambridge, Mass.

Participated · Series A · Sep 2021

ALGO ARTIS builds and provides Optium, a planning-optimization AI that automates highly complex operational plans such as production and shipping, reducing reliance on skilled planners. Optium has produced annual cost improvements ranging from several tens of millions to hundreds of millions of yen, reduced GHG emissions, and addressed knowledge concentration. The company reports four live deployments and is progressing multiple implementation projects across manufacturing, energy, rail/bus and other infrastructure sectors. ALGO ARTIS plans to use the new funding to strengthen Optium’s technical foundation, develop new services, and recruit top engineering, product and business talent. Founded in 2021 and based in Tokyo’s Chiyoda ward, the company emphasizes expanding Optium’s reach from individual sites to supply chains and wider social infrastructure. ALGO ARTIS builds and deploys optimization AI (algorithms) for social infrastructure, focusing on use cases like plant and logistics schedule management. The company emphasizes consulting, algorithm and feature design, prototyping, and iterative on-site improvements to ensure solutions are adopted in practice. Its predecessor work began inside DeNA from 2016, including a 2018 project with Kansai Electric on fuel-operation optimization for thermal power plants, and expanded through DeNA’s energy business office in 2019. In July 2021 the team spun out from DeNA to form ALGO ARTIS, with Kentarō Nagata as representative, and continues collaborating with DeNA as an equity-method affiliate. The company raised capital in a Series A to accelerate product development and hire engineers; a Series A extension was planned for September 2021.

Participated · Series A · Dec 2017

DocsApp operates an online doctor consultation platform and merged with digital consumer health business MediBuddy in a mixed cash-and-equity deal while continuing to run as a separate entity. The combined entity has raised a $20 million Series B to bolster doctor supply, patient reach, product and technology and expand its direct-to-consumer business. DocsApp was founded in 2015 by Satish Kannan and D Enbasekar and previously acquired patient-doctor engagement platform DocWise in August 2019. Post-merger the entity projects a customer base of three crores and a provider network of about 90,000 doctors, 7,000 hospitals, 3,000 diagnostic centres and 2,500 pharmacies. The company declined to disclose the ultimate holding-company arrangement pending completion of formalities. Bessemer is a common investor across the merged businesses. Phasorz Technologies operates DocsApp, a mobile doctor-consultation app launched in July 2015. DocsApp lets users upload symptoms and diagnostic reports, pay a consultation fee, and get one-on-one consultations via video call, voice call or in-built chat. The platform also supports ordering medicines and booking diagnostic tests online and offers consultations across 15 specialties including dermatology, gynecology and pediatrics. The company says it has onboarded more than 5,000 specialist doctors (up from 2,000 at its 2017 Series A) and claims around 6 million registered users across Tier-1 and smaller urban Tier-2 areas. Founded in 2013 by Satish Kannan and Enbasekar D., Phasorz is backed by investors including Bessemer Venture Partners, GSF Accelerator, Vijay Shekhar Sharma, Anupam Mittal and Srikanth Sundararajan. The company recently raised debt financing to support further growth, with the lead investor saying the funding will give DocsApp a fillip to scale. Phasorz Technologies operates DocsApp, a mobile-first doctor consultation platform that connects patients with specialist doctors for one-on-one chats or calls and supports medicine orders and diagnostic bookings. The platform on-boards only specialist doctors and aims to match patients with the right doctor in under 30 minutes after users upload symptoms and pay a consultation fee. DocsApp reports over 2,000 registered doctors across specialties including dermatology, gynaecology, paediatrics, psychiatry and general medicine. The Bengaluru-based company was founded in 2013 and launched DocsApp in July 2015. Management says it will use new funding for hiring, expanding operations, product development and outreach to recruit more doctors and extend services into remote and under-penetrated areas. The app previously raised $1.2 million and has backing from accelerators and angels. DocsApp is a Bangalore-based medical consultation app founded in 2015 by Satish Kannan and Enbasekar D. The platform lets patients chat with doctors and share images and reports across specialties including General Medicine, Gynecology, Psychiatry, Pediatrics, Weight Management, Sexology and Gastroenterology. The app is available for Android and iOS and has been downloaded more than 80,000 times. DocsApp is currently used by more than 15,000 patients every month from New Delhi, Bengaluru, Chennai, NCR, Mumbai, and Hyderabad. The company raised $1.2M in seed funding from Rebright Partners and angel investors Anand Rajaraman and Venky Harinarayan.

Participated · Seed · May 2017

Catalia Health is a San Francisco–based patient care management company founded in 2014 that offers an AI-powered personal healthcare companion called Mabu. The platform combines artificial intelligence, psychology and medical best practices to support patients managing chronic illnesses and to deliver daily, tailored check-ins. Mabu is deployed to help patients with conditions such as rheumatoid arthritis, late-stage kidney disease and congestive heart failure and to provide clinicians insight on adherence and patient status. Catalia positions its technology against a U.S. population of roughly 117 million people managing chronic conditions and targets improved medication adherence, symptom management and reduced readmissions. The company announced a hire for Director of Product Management to oversee the platform roadmap as it prepares clinical and commercial rollout. Catalia Health provides an AI-powered patient engagement platform that pairs proprietary conversation-generation algorithms with a social robot, Mabu, to engage patients, collect data, and support care management. The platform targets chronic-disease management and medication adherence, aiming to improve symptom management and reduce hospital readmissions. Catalia plans to build and deploy its care management system across its first three disease states and begin patient rollout in its first two disease states in early summer 2017. The company emphasizes scalable, personalized conversations to increase adherence and monitor patient health. Catalia was founded in 2014 and is based in San Francisco; Dr. Cory Kidd is CEO and founder. Financially, the company has completed a seed extension following an earlier seed round to fund product deployment and data collection. Catalia Health develops Mabu, a social robot designed to provide information and support for patients with chronic diseases such as diabetes, arthritis, cancer and heart disease. The company is pitching Mabu to healthcare providers and pharmaceutical companies to augment doctors and help manage large patient populations. Catalia has an alpha prototype in its offices and plans to scale production and deployment. The firm expects to have the first robots on the market by the end of the year and is already in discussions with several early potential customers. Founded by Cory Kidd using work that began at MIT’s Media Lab and evolved through his prior company Intuitive Automata, Catalia is positioning Mabu around engagement and the psychology of interaction. The company will use the recent financing to scale up its business.